Comparison tool

Vilon vs Epithalon side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

VilonEpithalon

Share this peptide comparison

Property	Vilon	Epithalon
Category	Bioregulators	Bioregulators
Also known as	Lys-Glu, KE Dipeptide	Epitalon, Epithalone, AGAG
FDA approved	No	No
Clinical status	Available in Russia - Not FDA approved Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Immune enhancement, thymic function, longevity	Longevity, telomere support, anti-aging, sleep
How it works	Vilon is presented as a short Lys-Glu dipeptide with a proposed bioregulatory mechanism. The source links it to hypotheses about cellular entry, nuclear effects, immune-related gene expression, DNA-repair gene expression, and chromatin changes seen in cultured lymphocytes. Those points are described as tentative; the supplied evidence does not establish precise molecular targets or independent validation comparable to an approved medicine.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typical dosing	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral or sublingual	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Research dosing	10-20 mg daily · 10-30 day courses · Oral capsules or sublingual	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typical duration	10-30 day courses	10-20 day cycles
Administration	Oral capsules or sublingual	Subcutaneous or intramuscular injection
Timing	Morning With or without food	Before bed With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Generally reported as well tolerated (Source wording is broad and does not substitute for systematic human safety data.) Brief injection-site discomfort (Listed by the source despite oral or sublingual administration also being reported.) Breast-cancer caution in mouse models (The source-reported mouse-model warning is retained conservatively; no human risk magnitude is established.) +1 more Limited human safety data (The supplied evidence does not provide robust human safety characterization.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 more Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Research summary	The source characterizes Vilon research as narrow and largely preclinical. It describes mouse work from Khavinson, Anisimov, and colleagues around 2000, including studies in female CBA mice that reported changes such as increased activity, small lifespan effects, and tumor-related outcomes. The same source stresses major limits: a single research lineage, modest reported effects, limited independent replication, and no registered Western randomized human trial evidence. Human anti-aging or immune-rejuvenation claims therefore remain extrapolations from early animal and laboratory findings.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
References	PubMed Springer +1 more ResearchGateA synthetic dipeptide vilon L-Lys-L-Glu inhibits growth of spontaneous tumors and increases life span of mice	PubMed PubMed +2 more WikipediaEpitalon Springer
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Vilon

Epithalon

Category

Bioregulators

Also known as

Lys-Glu, KE Dipeptide

Epitalon, Epithalone, AGAG

FDA approved

Clinical status

Available in Russia - Not FDA approved

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Immune enhancement, thymic function, longevity

Longevity, telomere support, anti-aging, sleep

How it works

Vilon is presented as a short Lys-Glu dipeptide with a proposed bioregulatory mechanism. The source links it to hypotheses about cellular entry, nuclear effects, immune-related gene expression, DNA-repair gene expression, and chromatin changes seen in cultured lymphocytes. Those points are described as tentative; the supplied evidence does not establish precise molecular targets or independent validation comparable to an approved medicine.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typical dosing

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral or sublingual

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Research dosing

10-20 mg daily · 10-30 day courses · Oral capsules or sublingual

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typical duration

10-30 day courses

10-20 day cycles

Administration

Oral capsules or sublingual

Subcutaneous or intramuscular injection

Timing

Morning

With or without food

Before bed

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Generally reported as well tolerated (Source wording is broad and does not substitute for systematic human safety data.)
Brief injection-site discomfort (Listed by the source despite oral or sublingual administration also being reported.)
Breast-cancer caution in mouse models (The source-reported mouse-model warning is retained conservatively; no human risk magnitude is established.)

+1 more

Limited human safety data (The supplied evidence does not provide robust human safety characterization.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 more

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Research summary

The source characterizes Vilon research as narrow and largely preclinical. It describes mouse work from Khavinson, Anisimov, and colleagues around 2000, including studies in female CBA mice that reported changes such as increased activity, small lifespan effects, and tumor-related outcomes. The same source stresses major limits: a single research lineage, modest reported effects, limited independent replication, and no registered Western randomized human trial evidence. Human anti-aging or immune-rejuvenation claims therefore remain extrapolations from early animal and laboratory findings.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

References

PubMed Springer

+1 more

ResearchGateA synthetic dipeptide vilon L-Lys-L-Glu inhibits growth of spontaneous tumors and increases life span of mice

PubMed PubMed

+2 more

WikipediaEpitalon Springer

Full profile

View Details